MVCD3
MCID: MCR113
MIFTS: 52

Microvascular Complications of Diabetes 3 (MVCD3)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Microvascular Complications of Diabetes 3

MalaCards integrated aliases for Microvascular Complications of Diabetes 3:

Name: Microvascular Complications of Diabetes 3 57 73 12 36
Diabetic Nephropathy 75 73 16 71
Microvascular Complications of Diabetes, Susceptibility to, 3 57 28 5
Mvcd3 57 73
End-Stage Renal Disease, Diabetic, Susceptibility to 57
Nephropathy, Diabetic, Susceptibility to 57
End-Stage Renal Disease, Diabetic 57
Diabetic End-Stage Renal Disease 73
Diabetic Nephropathies 53
Nephropathy, Diabetic 57

Classifications:



External Ids:

OMIM® 57 612624
OMIM Phenotypic Series 57 PS603933
MeSH 43 D048909
UMLS 71 C0011881

Summaries for Microvascular Complications of Diabetes 3

UniProtKB/Swiss-Prot: 73 Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary: Microvascular Complications of Diabetes 3, also known as diabetic nephropathy, is related to type 1 diabetes mellitus and lipid metabolism disorder. An important gene associated with Microvascular Complications of Diabetes 3 is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are ACE Inhibitor Pathway, Pharmacodynamics and Angiotensin II receptor type 1 pathway. The drugs Captopril and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include Kidney, endothelial and pancreas, and related phenotype is renal/urinary system.

Wikipedia: 75 Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function... more...

More information from OMIM: 612624 PS603933

Related Diseases for Microvascular Complications of Diabetes 3

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 668)
# Related Disease Score Top Affiliating Genes
1 type 1 diabetes mellitus 31.6 PVT1 NAGLU INS ALB AKR1B1 AGTR1
2 lipid metabolism disorder 31.4 MIR21 INS ALB ACE
3 hyperglycemia 31.3 NPHS1 MALAT1 INS ALB AKR1B1 AGTR1
4 renal fibrosis 31.2 TGFB1 MIR21 MIR192 CCN2 ALB AGTR1
5 uremia 31.2 INS ALB ACE
6 peripheral vascular disease 31.0 INS ALB ACE
7 hypertensive nephropathy 31.0 ALB ACE
8 membranous nephropathy 30.9 NPHS1 MIR192 CCN2 ALB
9 autonomic neuropathy 30.9 INS ALB AKR1B1
10 lipoid nephrosis 30.8 NPHS1 NAGLU ALB
11 membranoproliferative glomerulonephritis 30.8 NPHS1 ALB ACE
12 diabetic neuropathy 30.8 INS ALB AKR1B1 ACE
13 urinary tract infection 30.7 INS ALB ACE
14 atherosclerosis susceptibility 30.7 INS ALB AGTR1 ACE
15 glomerulonephritis 30.7 TGFB1 NPHS1 CCN2 ALB AGTR1 ACE
16 vascular disease 30.7 TGFB1 MIR21 INS ALB AGTR1 ACE
17 kidney hypertrophy 30.7 NPHS1 INS CCN2 ALB ACE
18 iga glomerulonephritis 30.7 TGFB1 NPHS1 ALB AGTR1 ACE
19 nephrotic syndrome 30.7 NPHS1 NAGLU INS ALB AGTR1 ACE
20 cardiovascular system disease 30.6 MIR217 MIR21 INS ALB AGTR1 ACE
21 hypoglycemia 30.6 INS ALB AKR1B1 ACE
22 fatty liver disease 30.6 MIR21 MIR192 MALAT1 INS
23 peripheral artery disease 30.6 MIR21 INS ALB ACE
24 cerebrovascular disease 30.6 MIR21 INS ALB AGTR1 ACE
25 renal artery atheroma 30.6 ALB AGTR1 ACE
26 congestive heart failure 30.5 INS ALB AGTR1 ACE
27 pyelonephritis 30.5 NAGLU ALB ACE
28 arteries, anomalies of 30.5 MIR21 INS ALB AGTR1 ACE
29 non-alcoholic fatty liver disease 30.5 MIR21 MIR192 INS ALB
30 diabetes mellitus, ketosis-prone 30.5 INS ALB ACE
31 apnea, obstructive sleep 30.5 INS ALB ACE
32 focal segmental glomerulosclerosis 30.4 TGFB1 NPHS1 ALB AGTR1 ACE
33 peripheral nervous system disease 30.4 MIR21 INS ALB AKR1B1 ACE
34 pre-eclampsia 30.4 NPHS1 MALAT1 INS ALB AGTR1 ACE
35 stroke, ischemic 30.4 MIR21 MALAT1 INS ALB AGTR1 ACE
36 chronic kidney disease 30.4 TGFB1 NPHS1 MIR21 INS CNDP1 CCN2
37 sleep apnea 30.4 INS ALB ACE
38 rapidly progressive glomerulonephritis 30.4 NPHS1 ALB ACE
39 macular retinal edema 30.4 INS ALB AKR1B1 ACE
40 renovascular hypertension 30.4 ALB AGTR1 ACE
41 diabetic polyneuropathy 30.3 INS ALB AKR1B1
42 lipoprotein quantitative trait locus 30.3 MIR21 INS CCN2 ALB AGTR1 ACE
43 miliary tuberculosis 30.2 ALB ACE
44 acute kidney tubular necrosis 30.2 NAGLU ALB ACE
45 nephrosclerosis 30.1 TGFB1 NPHS1 INS CCN2 AGTR1 ACE
46 hypokalemia 30.1 INS ALB ACE
47 alport syndrome 30.1 NPHS1 MIR21 ALB ACE
48 limb ischemia 30.1 MIR21 ALB ACE
49 diabetic macular edema 30.1 INS ALB AKR1B1
50 hypertensive retinopathy 30.1 ALB ACE

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 3:



Diseases related to Microvascular Complications of Diabetes 3

Symptoms & Phenotypes for Microvascular Complications of Diabetes 3

Clinical features from OMIM®:

612624 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 3:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.28 ACE AGTR1 AKR1B1 ALB INS MIR192

Drugs & Therapeutics for Microvascular Complications of Diabetes 3

Drugs for Microvascular Complications of Diabetes 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 297)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Captopril Approved Phase 4 62571-86-2 44093
2
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
3
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
4
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
5
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
6
Amlodipine Approved Phase 4 88150-42-9 2162
7
Atenolol Approved Phase 4 29122-68-7 2249
8
Doxazosin Approved Phase 4 74191-85-8 3157
9
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
10
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
11
Simvastatin Approved Phase 4 79902-63-9 54454
12
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
13
Insulin glulisine Approved Phase 4 207748-29-6
14
Insulin glargine Approved Phase 4 160337-95-1 118984454
15
Lixisenatide Approved Phase 4 320367-13-3 90472060 16139342
16
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
17
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
18
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
19
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
20
Carbamide peroxide Approved Phase 4 124-43-6
21
Candesartan cilexetil Approved Phase 4 145040-37-5
22
Nisoldipine Approved Phase 4 63675-72-9 4499
23
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
24
Probucol Approved, Investigational Phase 4 23288-49-5 4912
25
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
26
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
27
Atorvastatin Approved Phase 4 134523-00-5 60823
28
Indapamide Approved Phase 4 26807-65-8 3702
29
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
30
Trandolapril Approved Phase 4 87679-37-6 5484727
31
Saxagliptin Approved Phase 4 361442-04-8 11243969
32
Gliclazide Approved Phase 4 21187-98-4 3475
33
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
34
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
35
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
36
Canagliflozin Approved Phase 4 842133-18-0 74323022 24812758
37
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
38
Ertugliflozin Approved, Investigational Phase 4 1210344-57-2 75075340 44814423
39
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
40
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
41
Dapagliflozin Approved Phase 4 461432-26-8 9887712
42
Insulin lispro Approved Phase 4 133107-64-9 16132438
43
Insulin aspart Approved Phase 4 116094-23-6 16132418
44
Dulaglutide Approved, Investigational Phase 4 923950-08-7
45
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
46
Losartan Approved Phase 4 114798-26-4 3961
47
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
48
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
49
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
50
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181

Interventional clinical trials:

(show top 50) (show all 410)
# Name Status NCT ID Phase Drugs
1 Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study Unknown status NCT04127084 Phase 4 SGLT2 Inhibition
2 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
3 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
4 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
5 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
6 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
7 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
8 Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression Unknown status NCT04485845 Phase 4 Vildagliptin;Captopril Tablets;MetFORMIN 500 Mg Oral Tablet
9 Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy Unknown status NCT03664414 Phase 4 pentoxifylline
10 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
11 Effect of SGLT2 Inhibitor on Proteinuria in Diabetic Patients Unknown status NCT03573102 Phase 4 SGLT2 inhibitor;ACE inhibitor
12 Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria - A Double Blinded, Randomised, Placebo Controlled, Parallel, Single Center Study Unknown status NCT04061200 Phase 4 Semaglutide, 1.34 mg/mL;Empagliflozin 25 MG
13 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
14 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
15 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
16 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
17 A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus Completed NCT02276196 Phase 4 Lixisenatide;Insulin glulisine
18 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
19 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4 Ramipril
20 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Completed NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
21 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
22 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil 32mg
23 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
24 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
25 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
26 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
27 A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria Completed NCT02829177 Phase 4 Allopurinol;Placebo
28 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
29 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
30 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
31 Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen. Completed NCT00296296 Phase 4 Cyclosporin;Tacrolimus
32 Effect of Continuous Positive Airway Pressure on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea Completed NCT02816762 Phase 4 Pharmacological treatment
33 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH
34 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
35 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
36 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
37 Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes Completed NCT02914691 Phase 4 Dapagliflozine 10 mg once daily tablet treatment;Placebo identical once daily tablet treatment
38 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Completed NCT02690883 Phase 4 Exenatide;Lispro
39 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
40 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
41 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
42 A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil
43 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
44 A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA. Completed NCT01191983 Phase 4 Methoxy polyethylene glycol-epoetin beta [Mircera]
45 A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Patients With Diabetic Nephropathy Completed NCT04521049 Phase 4 Saxagliptin 5mg
46 A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus Completed NCT02682563 Phase 4 Dapagliflozin 10mg QD;Gliclazide 30mg QD
47 Effect of Glucose in Dialysis Water in Diabetics With Chronic Renal Failure on Blood Pressure, Pulse Rate, Plasma Glucose, Plasma Concentrations of Insulin, Growth Hormone, Renin, Angiotensin II, Endothelin and Body Temperature Completed NCT00438503 Phase 4
48 Comparative Effects of add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on Serum NT-PRO BNP and Proteinuria in Type 2 Diabetics With Nephropathy Completed NCT03006952 Phase 4 Pentoxifylline;Losartan
49 A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study Completed NCT00153023 Phase 4 Telmisartan;Valsartan
50 A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study) Completed NCT00168857 Phase 4 telmisartan;losartan

Search NIH Clinical Center for Microvascular Complications of Diabetes 3

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Microvascular Complications of Diabetes 3:
Mesenchymal precursor cells for type 2 diabetes
Embryonic/Adult Cultured Cells Related to Microvascular Complications of Diabetes 3:
Mesenchymal Precursor Cells (STRO-3 selected)

Genetic Tests for Microvascular Complications of Diabetes 3

Genetic tests related to Microvascular Complications of Diabetes 3:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes, Susceptibility to, 3 28 ACE

Anatomical Context for Microvascular Complications of Diabetes 3

Organs/tissues related to Microvascular Complications of Diabetes 3:

MalaCards : Kidney, Endothelial, Pancreas, Placenta, Heart, Bone Marrow, Monocytes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Microvascular Complications of Diabetes 3:
# Tissue Anatomical CompartmentCell Relevance
1 Kidney Podocyte Layer Podocytes Affected by disease, potential therapeutic candidate

Publications for Microvascular Complications of Diabetes 3

Articles related to Microvascular Complications of Diabetes 3:

(show top 50) (show all 21226)
# Title Authors PMID Year
1
Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. 53 62 57 5
7729604 1995
2
Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group. 53 62 57 5
7783416 1995
3
Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. 53 62 57 5
8314010 1994
4
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. 62 57 5
11687636 2001
5
The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. 62 57 5
10099885 1999
6
Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. 62 57 5
9120002 1997
7
Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene. 62 57 5
7909524 1994
8
Review: The role of microRNAs in kidney disease. 62 46
20883280 2010
9
Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. 62 46
20056746 2010
10
MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. 62 46
19450585 2009
11
ACE D/I polymorphism, migraine, and cardiovascular disease in women. 5
19221299 2009
12
MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. 62 46
18716028 2008
13
Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. 5
15635071 2005
14
The effects of the ACE gene insertion/deletion polymorphism on glucose tolerance and insulin secretion in elderly people are modified by birth weight. 5
15531537 2004
15
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. 5
15534175 2004
16
ACE1 polymorphism and progression of SARS. 5
15381116 2004
17
Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. 57
15164285 2004
18
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. 5
15277638 2004
19
A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. 5
15110771 2004
20
Alzheimer disease risk and genetic variation in ACE: a meta-analysis. 5
14872014 2004
21
Angiotensin-converting enzyme DD genotype is associated with worse perinatal cardiorespiratory adaptation in preterm infants. 5
14657821 2003
22
Phenotype modulators in myophosphorylase deficiency. 5
12666117 2003
23
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. 5
12220450 2002
24
Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. 5
11956052 2002
25
Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. 5
10841123 2000
26
Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population. 5
10643899 1999
27
A dominant relationship between the ACE D allele and serum ACE levels in a Ghanaian population. 5
10636736 1999
28
Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. 5
9916793 1999
29
Elite endurance athletes and the ACE I allele--the role of genes in athletic performance. 5
9737775 1998
30
ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. 5
9699903 1998
31
Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. 5
9259580 1997
32
D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. 5
9236417 1997
33
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. 5
8644984 1996
34
Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. 5
8675669 1995
35
Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. 5
8541160 1995
36
Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. 5
7593601 1995
37
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. 5
7854377 1995
38
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. 5
8170965 1994
39
Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. 5
8208911 1994
40
Genetic associations with human longevity at the APOE and ACE loci. 5
8136829 1994
41
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction. 5
8131299 1993
42
A potent genetic risk factor for restenosis. 5
8298638 1993
43
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction. 5
8131300 1993
44
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. 5
1328889 1992
45
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. 5
1386652 1992
46
Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. 5
1319114 1992
47
PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). 5
1313972 1992
48
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. 5
1976655 1990
49
Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. 5
2849100 1988
50
Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. 5
2847529 1988

Variations for Microvascular Complications of Diabetes 3

ClinVar genetic disease variations for Microvascular Complications of Diabetes 3:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ACE NM_000789.3(ACE):c.2306-117_2306-116insAF118569.1:g.14094_14382 INSERT Risk Factor
18061 GRCh37: 17:61565892-61565893
GRCh38: 17:63488531-63488532

Expression for Microvascular Complications of Diabetes 3

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 3.

Pathways for Microvascular Complications of Diabetes 3

GO Terms for Microvascular Complications of Diabetes 3

Biological processes related to Microvascular Complications of Diabetes 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.06 TGFB1 MIR21 INS CCN2 ACE
2 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.62 AGTR1 ACE
3 response to laminar fluid shear stress GO:0034616 9.54 TGFB1 ACE
4 negative regulation of miRNA-mediated gene silencing GO:0060965 9.43 TGFB1 PVT1
5 positive regulation of protein metabolic process GO:0051247 9.35 TGFB1 INS AGTR1
6 connective tissue development GO:0061448 9.26 TGFB1 CCN2
7 negative regulation of interleukin-21 production GO:0032705 9.16 MIR21 MIR192
8 mononuclear cell proliferation GO:0032943 8.8 TGFB1 ACE

Molecular functions related to Microvascular Complications of Diabetes 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metallodipeptidase activity GO:0070573 9.26 CNDP1 ACE
2 bradykinin receptor binding GO:0031711 8.92 AGTR1 ACE

Sources for Microvascular Complications of Diabetes 3

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....